These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 17853028

  • 1. Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.
    Nemoto K, Tomita Y.
    Scand J Urol Nephrol; 2007; 41(6):558-60. PubMed ID: 17853028
    [Abstract] [Full Text] [Related]

  • 2. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
    Masue N, Hasegawa Y.
    Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
    [Abstract] [Full Text] [Related]

  • 3. [Solitary peritoneal carcinomatosis in prostate cancer].
    Brehmer B, Makris A, Wellmann A, Jakse G.
    Aktuelle Urol; 2007 Sep; 38(5):408-9. PubMed ID: 17907070
    [Abstract] [Full Text] [Related]

  • 4. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N, Onishi T, Arima K, Sugimura Y.
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [Abstract] [Full Text] [Related]

  • 5. Unexpected response of hormone-refractory prostate cancer to treatment with an antileukemic chemotherapy regimen.
    Gandhok N, Sartor O.
    Urology; 2004 Oct; 64(4):807-9. PubMed ID: 15491730
    [Abstract] [Full Text] [Related]

  • 6. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
    Sciarra A, Di Silverio F.
    Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
    [Abstract] [Full Text] [Related]

  • 7. [Reevaluation of MAB therapy and progress of endocrine therapy].
    Klotz L, Payne H, Gillatt D, Keane T, Morris C, Akaza H, Hirao, Akakura K, Fukagai T.
    Gan To Kagaku Ryoho; 2005 May; 32(5):705-28. PubMed ID: 15934164
    [No Abstract] [Full Text] [Related]

  • 8. [Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy].
    Barbón JJ, González-Tuero J, Gay LL, Pérez-García FJ, Sampedro A.
    Arch Soc Esp Oftalmol; 2007 Nov; 82(11):715-7. PubMed ID: 17979041
    [Abstract] [Full Text] [Related]

  • 9. Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate.
    Molenaar JP, Baten A, Blokx WA, Hoogendam A.
    Eur Urol; 2009 Nov; 56(5):874-7; quiz 876. PubMed ID: 19171417
    [Abstract] [Full Text] [Related]

  • 10. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 11. Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial.
    Solberg A, Haugen OA, Viset T, Bergh A, Tasdemir I, Ahlgren G, Widmark A, Angelsen A.
    Int J Radiat Oncol Biol Phys; 2011 May 01; 80(1):55-61. PubMed ID: 20598453
    [Abstract] [Full Text] [Related]

  • 12. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
    Lau YK, Chadha MK, Litwin A, Trump DL.
    J Hematol Oncol; 2008 Nov 05; 1():21. PubMed ID: 18986533
    [Abstract] [Full Text] [Related]

  • 13. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T.
    Urology; 2007 Sep 05; 70(3):506-10. PubMed ID: 17905106
    [Abstract] [Full Text] [Related]

  • 14. Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies.
    Sartor O.
    J La State Med Soc; 2008 Sep 05; 160(2):99-100. PubMed ID: 18681353
    [Abstract] [Full Text] [Related]

  • 15. [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].
    Matveev BP, Bukharkin BV.
    Urologiia; 2001 Sep 05; (6):20-1. PubMed ID: 11785074
    [No Abstract] [Full Text] [Related]

  • 16. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG.
    Int J Radiat Oncol Biol Phys; 2009 Sep 01; 75(1):16-22. PubMed ID: 19289266
    [Abstract] [Full Text] [Related]

  • 17. [Results of 125-iodine seed implant with preplanning system in 250 patients with prostate cancer].
    Guinot JL, Ricós JV, Gimeno J, Tortajada MI, Carrascosa M, Santos M, Casanova J, Soler P, Crispín V, Arribas L.
    Actas Urol Esp; 2011 Jun 01; 35(6):339-44. PubMed ID: 21481974
    [Abstract] [Full Text] [Related]

  • 18. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Kishikawa H, Ichikawa Y.
    Int J Urol; 2007 Mar 01; 14(3):264-7. PubMed ID: 17430272
    [Abstract] [Full Text] [Related]

  • 19. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N, Arima K, Sugimura Y.
    Jpn J Clin Oncol; 2008 Sep 01; 38(9):617-22. PubMed ID: 18697759
    [Abstract] [Full Text] [Related]

  • 20. Cytology of metastatic prostate cancer following orchiectomy and antiandrogen therapy: a diagnostic challenge.
    Rapkiewicz A, Gorokhovsky R, Farcon E, Das K.
    Diagn Cytopathol; 2008 Jul 01; 36(7):499-502. PubMed ID: 18528888
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.